Glass House Brands Inc.
GLAS NYSE Medicinal Chemicals & Botanical Products Financials FY2020–FY2025
What Glass House Brands Inc. does
No business description yet.
- Legal name
- Glass House Brands Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 40-F · Mar 24, 2026
- Accession · CIK
- 0001848731-26-000015
0001848731
Revenue and margins
Glass House Brands Inc. had $182M of revenue in fiscal 2025, down 9.4% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$15.7M in fiscal 2025, −8.6% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Glass House Brands Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 8.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably Glass House Brands Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $54.1M | $14.1M | $32.5M | $36.9M | $23.4M |
| Debt incl. finance leases | $44.9M | $62.7M | $64.1M | $58.2M | $68.7M |
| Net debt / EBITDA | — | — | — | 1.1x | — |
| Debt / equity | 0.2x | 0.4x | 0.7x | 0.5x | 0.9x |
| Interest coverage | −13.2x | −7.4x | −5.0x | 0.6x | −2.3x |
| Current ratio | 1.2x | 0.7x | 0.6x | 1.0x | 1.8x |
| Quick ratio | 1.1x | 0.5x | 0.5x | 0.8x | 1.1x |
| Total assets | $288M | $351M | $304M | $311M | $319M |
| Total liabilities | $106M | $129M | $159M | $146M | $144M |
| Shareholders' equity | $182M | $169M | $89.8M | $116M | $73.9M |
| Net debt (− = net cash) | −$9.2M | $48.5M | $31.5M | $21.3M | $45.3M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✓ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✓ | ✓ | ✓ |
| Return on assets rose | — | ✓ | ✓ | ✕ | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | ✓ | ✕ | ✕ | ✓ | ✕ |
| Current ratio rose | — | ✓ | ✕ | ✕ | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✕ | ✕ |
| Gross margin rose | — | ✕ | ✕ | ✓ | ✕ | ✕ |
| Revenue rose relative to assets | — | ✕ | ✓ | ✓ | ✓ | ✕ |
| F-score | — / 3 | 4 / 9 | 2 / 9 | 4 / 9 | 7 / 9 | 3 / 9 |
| Accruals ratio | −12.9% | −12.8% | 2.5% | −37.1% | −9.1% | −13.1% |
| Altman Z'' | −0.83 | 0.59 | −0.86 | −3.37 | −1.05 | −1.45 |
6 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $48.3M | $63.2M | $84.9M | $161M | $201M | $182M |
| Gross profit | $18.7M | $15.8M | $20.7M | $81.0M | $97.4M | $77.0M |
| Operating income | −$6.0M | −$36.2M | −$56.4M | −$49.5M | $5.7M | −$16.5M |
| Interest expense | $2.2M | $2.7M | $7.6M | $9.8M | $9.2M | $7.1M |
| Pretax income | −$10.2M | −$41.3M | −$37.3M | −$88.1M | $11.2M | −$17.0M |
| Income tax | $6.4M | $2.0M | −$4.4M | $9.9M | $10.5M | $11.9M |
| Net income | −$16.7M | −$43.1M | −$32.9M | −$98.3M | $0.5M | −$29.7M |
| Net income to common | — | −$44.9M | −$53.2M | −$117M | −$15.4M | −$45.1M |
| Diluted EPS | −$0.78 | −$1.11 | −$0.83 | −$1.62 | −$0.21 | −$0.55 |
| Diluted shares | 0.02B | 0.04B | 0.06B | 0.07B | 0.08B | 0.08B |
| Cash flow | ||||||
| Cash from operations | −$7.7M | −$20.3M | −$40.8M | $23.2M | $28.4M | $11.4M |
| Capital expenditure | $3.9M | $108M | $27.8M | $12.3M | $10.3M | $27.2M |
| Free cash flow | −$11.5M | −$129M | −$68.6M | $10.9M | $18.1M | −$15.7M |
| Depreciation and amortization | $2.4M | $4.6M | $11.3M | $13.5M | $14.3M | $15.0M |
| Stock-based compensation | $2.5M | $8.7M | $12.8M | $7.6M | $13.1M | $13.4M |
| Acquisitions | $0.1M | $0.3M | −$2.8M | — | — | — |
| Balance sheet | ||||||
| Cash and short-term investments | $4.5M | $54.1M | $14.1M | $32.5M | $36.9M | $23.4M |
| Total debt | $16.0M | $44.9M | $62.7M | $64.1M | $58.2M | $68.7M |
| Current assets | $18.5M | $68.6M | $38.9M | $49.2M | $66.1M | $67.7M |
| Current liabilities | $19.6M | $55.2M | $54.0M | $87.4M | $66.5M | $38.0M |
| Inventory | $6.9M | $6.5M | $11.0M | $8.8M | $14.3M | $26.2M |
| Property and equipment, net | $27.2M | $196M | $216M | $216M | $212M | $229M |
| Goodwill | $4.8M | $4.9M | $37.8M | $0.0M | $0.0M | — |
| Intangible assets | $5.3M | $5.6M | $35.9M | $21.2M | $14.2M | $11.6M |
| Total assets | $69.5M | $288M | $351M | $304M | $311M | $319M |
| Total liabilities | $43.3M | $106M | $129M | $159M | $146M | $144M |
| Shareholders' equity | $26.3M | $182M | $169M | $89.8M | $116M | $73.9M |
| Margins | ||||||
| Gross margin | 38.8% | 25.0% | 24.4% | 50.3% | 48.5% | 42.3% |
| Operating margin | −12.4% | −57.2% | −66.4% | −30.8% | 2.9% | −9.1% |
| EBITDA margin | −7.5% | −50.0% | −53.1% | −22.4% | 10.0% | −0.8% |
| Net margin | −34.5% | −68.2% | −38.8% | −61.1% | 0.3% | −16.3% |
| FCF margin | −23.9% | −203.8% | −80.8% | 6.8% | 9.0% | −8.6% |
| Returns | ||||||
| Return on capital | −12.6% | −16.5% | −20.5% | −32.3% | 2.7% | −11.0% |
| Return on capital employed | −12.0% | −15.6% | −19.0% | −22.9% | 2.4% | −5.9% |
| Return on equity | −63.4% | −41.4% | −18.7% | −76.0% | 0.5% | −31.2% |
| Return on assets | −24.0% | −24.1% | −10.3% | −30.0% | 0.2% | −9.4% |
| Return on tangible equity | −103.0% | −26.2% | −55.9% | −170.3% | −15.1% | −72.3% |
| Growth | ||||||
| Revenue growth | — | 30.9% | 34.3% | 89.5% | 24.9% | −9.4% |
| Net income growth | — | — | — | — | — | −5,814.6% |
| FCF growth | — | — | — | — | 65.8% | −186.9% |
| Share count change | — | 89.4% | 59.3% | 12.2% | 4.4% | 8.9% |
| Financial health | ||||||
| Net debt / EBITDA | — | — | — | — | 1.1x | — |
| Debt / equity | 0.6x | 0.2x | 0.4x | 0.7x | 0.5x | 0.9x |
| Interest coverage | −2.8x | −13.2x | −7.4x | −5.0x | 0.6x | −2.3x |
| Current ratio | 0.9x | 1.2x | 0.7x | 0.6x | 1.0x | 1.8x |
| Quick ratio | 0.6x | 1.1x | 0.5x | 0.5x | 0.8x | 1.1x |
| Capital allocation | ||||||
| Capex / revenue | 8.0% | 171.7% | 32.7% | 7.7% | 5.1% | 14.9% |
| Stock comp / revenue | 5.3% | 13.8% | 15.0% | 4.7% | 6.5% | 7.4% |
| Quality scores | ||||||
| Piotroski F-score | — | 4.0 | 2.0 | 4.0 | 7.0 | 3.0 |
| Altman Z'' | −0.8 | 0.6 | −0.9 | −3.4 | −1.0 | −1.4 |
| Accruals ratio | −12.9% | −12.8% | 2.5% | −37.1% | −9.1% | −13.1% |
Source: SEC EDGAR XBRL filings (CIK 0001848731). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.
